December 12, 2025 4:52pm

As I wrote in yesterday’s a.m. post; Capricor Therapeutics (CAPR -$1.16 after Thursday’s -$1.49) was again pre-ordained to the downside, right again with more -$ to follow! My conviction STANDS! <see The Bottom Line>

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision

It’s not always time to buy or sell; but it is time to KNOW and why!

Never leave an investor uninformed! 

TGIF, the sooner the market closes, the cocktail hour or 2 begins

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!

Friday’s RMi Pre-opening Bell: Limit the risk and its exposure! … https://www.regmedinvestors.com/articles/14227

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): I reiterate WHO is PACKING the Pig that’s Broke … https://www.regmedinvestors.com/articles/13812

I also, follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Friday: The Dow closed DOWN -245.96 points or -0.51%, the S&P closed DOWN -73.59 points or -1.07% while the Nasdaq closed DOWN -398.686 points or -1.69%

  • Theme of the session: bogged-down by tech firms share pricing declines

Friday’s (my) 40-company covered sector’s advance/decline line opened negative with 16 incliners, 22 decliners and 2 flats ending with a negative close of 12 incliners, 26 decliners and 2 flats

  • Indexes and equities; another day of the rotation trade

Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C&GT) sector

  • Philadelphia Fed President Anna Paulson said Friday she views unemployment as a bigger economic threat than inflation, suggesting more room for cutting interest rates.

The CBOE Fear (VIX) index closed at 15.81 after Thursday’s 14.85, Wednesday’s 15.84, Tuesday’s 16.90 and Monday’s 16.55

 

Metrics: Friday …

  • The RUT was down -39.15 points or -1.51%,
  • The XLV was up +0.48 points or +0.31%,
  • The NBI was down -15.84 points or -0.28%;
  • The XBI was up +0.11 points or +0.09%
  • The IWM was down -3.90 or -1.51%;
  • The IBB was down -0.86 points or -0.51%,
  • The VIX was up +0.96 points or +6.46% at to 15.81

 

Q4 – December – 4 positive and 6 negative closes

  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Friday Closing UP (11 of 11)

  • Vertex (VRTX +$6.11 after Thursday’s +$1.29 after Wednesday’s +$7.63 after Tuesday’s -$5.03 after Monday’s -$13.44),
  • Ionis Pharmaceuticals (IONS +$1.68 after Thursday’s +$0.51 after Wednesday’s +$0.23 after Tuesday’s -$2.65 after Monday’s -$0.17),
  • Regenxbio (RGNX +$1.02 after Thursday’s -$0.21 after Wednesday’s +$0.34 after Tuesday’s -$0.52),
  • Supernus Therapeutics (SUPN +$0.65 after Thursday’s +$0.35 after Wednesday’s +$0.74 after Tuesday’s -$1.74 after Monday’s +$1.48),
  • AxoGen (AXGN +$0.41),
  • Entrada Therapeutics (TRDA +$0.27 after Thursday’s +$0.22)
  • Harvard Apparatus RT (OTCQB: HRGN +$0.12 with 4,615 shares traded after Thursday’s $0.00, Wednesday’s -$0.06 with 600 shares traded, Tuesday’s $0.00 with 600 shares traded and Monday’s +$0.18 with 6,900 shares traded) – manipulating the up for downslide, PONZI scheme?
  • Precigen (PGEN +$0.07),
  • MiMedx (MDXG +$0.06)
  • Fate Therapeutics (FATE +$0.04),
  • Ultragenyx Pharmaceuticals (RARE +$0.03),

Flat (3)

  • Adverum Biotechnologies ADVM) – acquired
  • Brainstorm Cell Therapeutics (BCLI)
  • Solid Biosciences (SLDB)

Friday’s Closing DOWN (10 of 26):

  • Alnylam Pharmaceuticals (ALNY -$15.08 after Thursday’s +$8.17 after Wednesday’s -$10.76 after Tuesday’s -$14.81 after Monday’s -$28.10),
  • Lenz Therapeutics (LENZ -$6.36 after Thursday’s -$0.54 after Wednesday’s -$1.41),
  • IQVIA Holdings (IQV -$3.72 after Thursday’s +$3.06 after Wednesday’s +$5.19 after Tuesday’s -$5.51 after Monday’s -$2.28),
  • CRISPR Therapeutics (CRSP -$1.41 after Thursday’s +$0.50 after Wednesday’s +$0.55),
  • BioNTech (BNTX -$1.19 after Thursday’s +$0.26 after Wednesday’s -$0.11),
  • Capricor Therapeutics (CAPR -$1.16 after Thursday’s -$1.49 after Wednesday’s +$1.29 after Tuesday’s -$1.18 after Monday’s +$1.67),
  • Vericel (VCEL -$0.85 after Thursday’s -$0.25 after Wednesday’s -$0.74 after Tuesday’s +$1.08 after Monday’s +$1.07),
  • Arrowhead Pharma (ARWR -$0.73 after Thursday’s +1.95),
  • Cellectis SA (CLLS -$0.54),
  • Intellia Therapeutics (NTLA -$0.53),
  • BioLife Solutions (BLFS -$0.49)

 

The Bottom Line: More of the … WHYs

Back on the merry-go-round …

Most C&GT sector equities declined Friday and Thursday after inclining Wednesday then declining on Tuesday, follow-by positive closes on Monday, then last Friday’s dive, Thursday and Wednesday positive closes following negative closes on the previous Tuesday and Monday.

For the week:

  • The S&P 500 is down 42.99 points, or 0.6%.
  • The Dow is up 503.06 points, or 1%.
  • The Nasdaq is down 382.96 points, or 1.6%.
  • The Russell 2000 is up 29.97 points, or 1.2%.

 

Maintaining MY opinion (from title): Capricor Therapeutics (CAPR) is overvalued, overbought and headed to a BIG slide … I would also ask if the SEC should investigate the post news run-up and the sudden offering financing pricing … 12/2 pricing, $6.36, offering price of $25.00 to today’s $26.02???

Not anyone else is on the same page:

  • Remaining risks are tied to HOPE-3 and potential priority review dynamics
  • Make your own decision to CUT-BACK as regulatory moving pieces will shape the investment narrative
  • Investors may wish to stay informed to better track and interpret future shifts in CAPR's soon to be evolving story – can you afford to wait and possibly take a hit out-of-the-blue.

 

Take it a session at a time … the REAL question is … how long will this sentiment and conviction “run” last in the “clean-out-the-exposure” December?

A question does NOT answer an inquiry; investors need more than a few catalysts that could revive a rally, I do NOT expect end end-of-year flurry!

  • Depleted market valuations and the uncertain payoff from heavy spending as we get closer to 2025 ends and then coming Q4 and FY25 financial and achievement results

 

2nd December week:

  • 12/12 – Friday closed negative with 12 positive, 26 negative and 2 flats
  • 12/11 – Thursday closed negative with 18 positive, 19 negative and 3 flats
  • 12/10 – Wednesday closed positive with 24 positive, 12 negative and 4 flats
  • 12/9 - Tuesday closed negative with 10 positive, 27 negative and 3 flats
  • 12/8 - Monday closed positive with 22 positive, 16 negative and 2 flat

Last week,  

  • 12/5 – Friday closed negative with 13 positive, 26 negative and 1 flat
  • 12/4 – Thursday closed positive with 26 positive, 12 negative and 2 flats
  • 12/3 – Wednesday closed positive with 35 positive, 4 negative and 1 flat
  • 12/2 - Tuesday closed negative with 10 positive, 29 negative and 1 flat
  • 12/1 – Monday closed negative with 5 positive, 31 negative and 0 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

A real question, are cell and gene therapy (C&GT) sector companies with high insider ownership present … opportunity?

  • Do they often demonstrate alignment between management and shareholder interests … a critical factor in navigating volatile market conditions?
  • I will be looking into this …! Stay tuned.

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
  • “I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!”

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:   

  • Friday: Vertex (VRTX), Regenxbio (RGNX) and Supernus Therapeutics (SUPN)
  • Thursday: Alnylam Pharmaceuticals (ALNY), IQVIA Holdings (IQV) and Arrowhead Pharma (ARWR)
  • Wednesday: Vertex (VRTX), IQVIA Holdings (IQV) and Capricor Therapeutics (CAPR)
  • Tuesday: Wave Life Sciences (WVE), Mesoblast (MESO) and Vericel (VCEL)
  • Monday: Wave Life Sciences (WVE), Arrowhead Pharma (ARWR) and Capricor Therapeutics (CAPR)

The worst three (3) in the session:

  • Friday: Alnylam Pharmaceuticals (ALNY), IQVIA Holdings (IQV) and Arrowhead Pharma (ARWR)
  • Thursday: Wave Life Sciences (WVE), Capricor Therapeutics (CAPR) and Mesoblast (MESO)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and Wave Life Sciences (WVE)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), IQVIA Holdings (IQV) and Vertex (VRTX)
  • Monday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and AxoGen (AXGN),

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.